Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 12/20 | 0.70 |
| ▸ | KDR | P35968 | 4/20 | 0.57 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.57 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.57 |
| ▸ | KIT | P10721 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1591190 | 0.90 | AXL (0.71) | AXLKDRPDGFRAFGFR2KIT | |
| SCHEMBL1592177 | 0.89 | AXL (0.72) | AXLKDRPDGFRAFGFR2KIT | |
| SCHEMBL1590997 | 0.86 | AXL (0.73) | AXLKDRPDGFRAFGFR2KIT | |
| SCHEMBL12702756 | 0.85 | AXL (0.74) | AXLKDRPDGFRAFGFR2KIT | |
| SCHEMBL1591490 | 0.83 | AXL (0.62) | AXLKDRPDGFRAFGFR2KIT | |
| SCHEMBL1590740 | 0.83 | AXL (0.82) | AXLKDRPDGFRAFGFR2KIT | |
| SCHEMBL1591824 | 0.83 | AXL (0.77) | AXLKDRPDGFRAFGFR2KIT | |
| SCHEMBL1592017 | 0.83 | AXL (0.80) | AXLKDRPDGFRAFGFR2KIT | |
| SCHEMBL13667536 | 0.82 | THRB (0.48) | AXLKITPOLBMAPK1THRB | |
| SCHEMBL1592015 | 0.82 | AXL (0.84) | AXLKDRPDGFRAFGFR2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-04-21 | — | — | US | claimed |
| US-9206130-B2 | Quinoline derivatives as AXL kinase inhibitors | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-08 | — | — | US | disclosed |
| US-9206130-B2 | Quinoline derivatives as AXL kinase inhibitors | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-08 | — | — | US | disclosed |
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | AXL, FLT3, TYRO3 | AXL 1/4885KDR 105/4885PDGFRA 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.